Background and objective: The benefits of domiciliary non-invasive ventilation (NIV) post lung transplantation (LTx) have not previously been described. This was a single-centre retrospective audit of patients requiring domiciliary NIV post-LTx. Our aim was to describe indications for NIV and outcomes in chronic lung allograft dysfunction (CLAD) and diaphragmatic palsy. Methods: All patients requiring domiciliary NIV postLTx between 2010 and June 2016 were assessed. NIV indications, respiratory function and patient outcomes were collected. Results: Out of 488 LTx recipients, 20 patients were identified as requiring NIV over the 6.5-year study period. The most common indications for NIV were CLAD and diaphragmatic palsy. Hypercapnia improved significantly with NIV. Patient outcomes were poor with nine (45%) patients dying, four (20%) undergoing redoLTx, four (20%) continuing domiciliary NIV and only three (15%) patients weaned off NIV. Conclusion: This is the first case series to describe the use of domiciliary NIV post-LTx. Patients commenced on NIV post-LTx had severely impaired lung function and severe hypercapnia. Patients with diaphragmatic palsy often recovered. The mortality rate was high in chronic allograft dysfunction.
INTRODUCTION
Domiciliary non-invasive ventilation (NIV) is an important treatment modality for patients with chronic ventilatory failure. It improves quality of life and survival in patients with neuromuscular disease and chest wall disorders. 1 NIV also improves hypercapnia and quality of life in patients with obesity hypoventilation syndrome 2 and cystic fibrosis. 3 Its role in chronic obstructive pulmonary disease (COPD) is less straightforward with a recent meta-analysis showing no clinical benefits 4 whilst two trials have shown a significant mortality benefit. 5, 6 Lung transplantation (LTx) is an established treatment for patients with chronic lung disease causing respiratory failure. 7 The use of NIV post-LTx in the acute post-operative period gives encouraging results. It facilitates early extubation, reduces the need for reintubation and assists in the management of early lung allograft dysfunction and diaphragm palsies post phrenic nerve injury. 8 However, its use post-LTx in the chronic or domiciliary setting has not previously been described in the literature.
The aim of this study was to describe indications and outcomes of patients post-LTx requiring domiciliary NIV. The study was performed at the Alfred Hospital Lung Transplantation Service 9 that has post-transplant survival rates comparable to international survival data. 10 
METHODS
We performed a retrospective analysis of all patients who had undergone LTx and commenced domiciliary NIV between January 2010 and June 2016. Patient data were collected until September 2016, resulting in a minimum 
SUMMARY AT A GLANCE
Domiciliary non-invasive ventilation (NIV) post lung transplantation (LTx) is seldom required. LTx recipients with ventilatory failure secondary to chronic lung allograft dysfunction may benefit from NIV as a bridge to redo-LTx or as a palliative measure. LTx recipients with diaphragmatic palsy may be weaned off NIV as they recover.
follow-up of 3 months. Patients were followed up until death or retransplantation, with a median follow-up period of 25 months (range: 3-78 months). Ethics approval was granted by the Human Research Ethics Committee at the Alfred Hospital.
The data collected included LTx type (bilateral vs single), aetiology of initial lung disease, indication for NIV, duration between LTx and NIV commencement, lung function measures at the time of NIV commencement, arterial blood gas (ABG) measures at commencement and post-stabilization on NIV, NIV pressures, NIV compliance and patient outcomes such as death or retransplantation. Data were summarized using mean AE SD, median (interquartile range (IQR)) or number (%) wherever appropriate. The Kaplan-Meier method was used to plot survival post-LTx as a function of time and comparisons between curves were made using the log-rank test. A two-sided P-value of less than 0.05 indicated statistical significance. Analyses were performed with Stata software version 14 (StataCorp, College Station, TX, USA).
RESULTS
Of the 488 patients who underwent LTx, 20 (4.1%) received domiciliary NIV over the 6.5-year study period. The patient demographics are listed in Table 1 . The mean age of the LTx patients commencing NIV was 54.2 years. This is consistent with our centre's LTx recipient demographics and reflects the increasing age of LTx recipients. 10 The majority of patients underwent bilateral LTx.
The two main indications for NIV were the development of chronic lung allograft dysfunction (CLAD) and diaphragm palsy. Several patients had a combination of factors, including obstructive sleep apnoea (OSA), nocturnal hypoventilation, diaphragm paralysis, myopathy, primary graft dysfunction and CLAD. NIV was commenced at a median of 9 months post-LTx. Those who required NIV for CLAD commenced therapy at a median time period of 45 months post-LTx.
Three LTx recipients required NIV immediately after extubation and a further two recipients commenced NIV within 1 month of being transplanted. These patients all had diaphragm palsies confirmed on ultrasound screening. The incidence of diaphragm palsies in the LTx cohort during the period examined ranged from 6.9% 11 to 20%; however, only 1% of the LTx cohort required NIV for this indication.
The majority of patients commenced NIV during an inpatient stay in the setting of acute-on-chronic hypercapnic respiratory failure, with only 4 of the 20 patients commencing NIV semi-electively in the outpatient setting. There was substantial improvement in pH and partial pressure of carbon dioxide (PCO 2 ) with NIV. Mean arterial carbon dioxide partial pressure (PaCO 2 ) improved from 74 mm Hg (AE16) to 51 mm Hg (AE8) pre-and post-stabilization on NIV. Mean NIV pressures were inspiratory positive airway pressure (IPAP) of 17 cm H 2 O and expiratory positive airway pressure (EPAP) of 7 cm H 2 O, the mean back up respiratory rate was 14 breaths per minute.
Four patients underwent in-laboratory polysomnography (PSG) for NIV titration with a further 14 patients having overnight oximetry for titration purposes. The remainder were titrated on serial ABG measures. Ten patients required supplemental oxygen in addition to NIV.
NIV compliance was high with a mean daily usage of 9 h. The median duration of NIV use post-LTx was 10 months. Three of the five patients with diaphragm palsies, who needed NIV use immediately post-LTx, were weaned off successfully. The remaining two required NIV until death, one from subsequent development CLAD and one from metastatic oesophageal cancer. Nine patients died using NIV, two of these were on a waiting list for a redo-LTx. Four patients underwent a redo-LTx and did not require NIV post redoLTx. Four patients continued domiciliary NIV ( Table 2 ).
In the cohort requiring NIV the overall retransplantfree survival was 40% at 25 months (Fig. 1) . Retransplant-free survival was 35% at the end of follow-up with a median survival of 40.5 months. This is lower compared with overall survival post-LTx worldwide 10 and lower than the overall transplant survival at our own institution which is 85% at 2 years and 76% at 5 years. Those who required NIV within 9 months of LTx had worse survival compared with those who commenced NIV 9 or more months post-LTx; however, this was not statistically significant (P = 0.71) (Fig. 2) . The survival post -LTx according to NIV indication is depicted in Figure 3 .
DISCUSSION
This is the first case series of patients requiring domiciliary NIV post-LTx. Domiciliary NIV use post-LTx was offered to a small number of patients after LTx; however, it is an important consideration, particularly in those with CLAD and diaphragm palsies-associated hypercapnic ventilatory failure.
As survival continues to improve post-LTx, 12 it is possible that an increasing number of patients may benefit from domiciliary NIV to manage their ventilatory failure. With better survival and more aggressive management of CLAD, it is also possible that there will be a reduction of ventilatory failure and therefore NIV.
We do not yet have complete data for incidence of CLAD and severe bronchiolitis obliterans syndrome (BOS) for our latest cohort. We can extrapolate from our registry data that the 1-and 5-year incidence of CLAD is 15% and 35%, respectively, and 1-and 5-year incidence of BOS is 3% and 15%, respectively. A conservative extrapolation based on these figures suggests 150 LTx recipients of our cohort of 488 may suffer from CLAD. Despite an overall incidence of CLAD of 30.7%, only 4.1% required NIV. This suggests a relatively low incidence of hypercapnic ventilatory failure in our CLAD population given that all those who presented with recurrent acute or progressive chronic ventilatory failure were identified as requiring domiciliary NIV.
There are several possibilities to explain this observation. CLAD encompasses a variety of specific conditions such as chronic lung rejection and infection but the overall phenotype is of loss of lung function leading to chronic ventilatory failure. Comparisons between COPD and CLAD have been drawn, and the predominant feature in most patients suffering from CLAD is BOS leading to small airway obstruction. 13 The use of NIV in stable hypercapnic COPD is controversial; however, a recent trial showed significant improvement in PCO 2 , symptoms, quality of life, forced expiratory volume in 1 s (FEV 1 ) and mortality. 6 With a similar physiological phenotype, it is tempting to extrapolate these data to patients with CLAD and hypercapnic respiratory failure. This, however, does not explain the relatively low incidence of NIV use in our CLAD cohort. Perhaps, our CLAD cohort has a wider range of pathologies contributing to ventilatory failure as evidenced by the discrepancy between our centre's rates of CLAD compared with BOS. Restrictive allograft syndrome (RAS) may be more of a significant contributor to CLAD in our cohort. Furthermore, those at the milder end of the spectrum (nocturnal hypoventilation only) may be underdiagnosed and undertreated, because not all patients underwent PSG or overnight oximetry.
The use of domiciliary NIV for post-LTx patients with diaphragm palsies is uncommon. Previous research at our institution suggests an incidence of diaphragm palsies of 6.9%. More judicious screening and identification of phrenic nerve injuries suggests an overall incidence of 20%. Over half of these resolve or partially recover by 18 months post-LTx and only 1% require NIV; most patients are able to be weaned off NIV.
Overall, the outcomes of those requiring NIV postLTx were poor. A proportion were retransplanted, many were not suitable candidates for a second transplant or died on the waitlist. NIV may palliate symptoms, improve quality of life in patients who are unsuitable for retransplantation and reduce hospitalizations. NIV may also provide a bridging therapy to , NIV commenced before 9 months). NIV, non-invasive ventilation.
stabilize ventilation for those waiting for retransplant, accepting that some may progress despite attempted control of ventilatory failure. It is not clear whether NIV improves survival post-LTx and further study is required to assess this.
There are some important limitations. First, due to the nature of this study, no case-matched controls were studied to assess the true impact of the NIV. This nature of study also lent itself to selection bias because only certain patients were identified and included; however, all patients with ventilatory failure were assessed for the need of NIV. The retrospective nature of this study also limited a standardized approach to NIV commencement and titration. The small number of patients included in the study limits the conclusions that can be drawn about the effects of NIV.
Overall, domiciliary NIV appeared to have a role for patients' post-LTx. Patients who required NIV early post-LTx for diaphragm palsies were weaned off NIV if their diaphragm palsy improved. In this case series, patients with chronic ventilatory failure secondary to CLAD continued NIV until a lung retransplantation or as a palliative measure until death. It is not certain if it improves survival and/or quality of life. Still, as LTx numbers increase and survival improves, domiciliary NIV may have an increasing role in the management of patients post-LTx with chronic hypercapnic ventilatory failure. , diaphragm palsy; , hypoventilation). CLAD, chronic lung allograft dysfunction; NIV, non-invasive ventilation.
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